文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

纳武利尤单抗促进异基因移植后移植物抗肿瘤效应的I期研究

Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2026-10-16

这项前瞻性I期研究评估了PD-1抑制剂纳武利尤单抗在异基因造血干细胞移植后复发/难治血液肿瘤中增强移植物抗肿瘤效应的安全性和疗效。髓系肿瘤或急性淋巴细胞白血病患者无进展生存和总生存劣于慢性淋巴系统肿瘤患者。9例严重不良事件发生,包括4例因移植物抗宿主病或肺炎导致的剂量限制性毒性。

要点

  • 纳武利尤单抗可促进异基因移植后移植物抗肿瘤效应,尤其在淋巴系统肿瘤中。
  • 髓系肿瘤或急性淋巴细胞白血病患者无进展生存和总生存劣于慢性淋巴系统肿瘤患者。
  • 基线T细胞活化表型及GZMA、GZMB、PRF1表达或可预测获益人群。

核心结论

  • 纳武利尤单抗可促进异基因造血干细胞移植后移植物抗肿瘤效应,尤其在淋巴系统肿瘤中。

研究设计与样本

  • 纳武利尤单抗每2周给药一次,最多48周。

主要发现

  • 6例达完全缓解,均为慢性淋巴系统肿瘤。
  • 髓系肿瘤或急性淋巴细胞白血病患者无进展生存为4.3个月 vs 11.7个月(p < 0.05),总生存为43.6个月 vs 未定义(p < 0.05),均劣于慢性淋巴系统肿瘤患者。
  • 发生9例严重不良事件,包括4例因移植物抗宿主病或肺炎导致的剂量限制性毒性。
  • 发生移植物抗宿主病的患者基线T细胞活化更高并早期达临床缓解。

关键数值与推荐

  • 基线效应记忆T细胞、HLA-DR及GZMA、GZMB、PRF1基因表达可作为生物标志物帮助识别最可能从挽救性检查点抑制中获益的患者。

临床怎么用

  • 对异基因移植后复发的慢性淋巴系统肿瘤患者,可考虑纳武利尤单抗促进移植物抗肿瘤效应。
  • 治疗中需密切监测移植物抗宿主病和肺炎等剂量限制性毒性。
  • 基线T细胞表型和颗粒酶/穿孔素基因表达或有助于筛选获益人群。

局限性

  • 未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor-derived T cells to mediate the graft-versus-tumour (GVT) effect, but relapse may result from impaired immune reconstitution, tumour antigen downregulation or T-cell exhaustion. This prospective phase I study evaluated the safety and efficacy of the PD-1 inhibitor, nivolumab, in enhancing GVT post-alloHSCT and explored the impact of baseline T-cell phenotypes on clinical outcomes. Fourteen patients with relapsed/refractory haematological malignancies post-alloHSCT received nivolumab every 2 weeks for up to 48 weeks. Six achieved complete remission, all with chronic lymphoid malignancies. Patients with myeloid malignancies or acute lymphoblastic leukaemia had inferior progression-free survival (4.3 vs. 11.7 months, p < 0.05) and overall survival (43.6 months vs. undefined, p < 0.05) than those with chronic lymphoid malignancies. Nine serious adverse events occurred, including four dose-limiting toxicities due to graft-versus-host disease (GVHD) or pneumonitis. Patients who developed GVHD had higher T-cell activation at baseline and achieved early clinical responses. These findings confirm that nivolumab can promote GVT post-alloHSCT, particularly in lymphoid disorders. Baseline immunophenotype (effector memory T cells, Human Leukocyte Antigen - DR isotype [HLA-DR]) and gene expression (granzyme A [GZMA], granzyme B [GZMB], perforin [PRF1]) can be used as biomarkers to help identify patients most likely to benefit from salvage checkpoint inhibition.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ngo TQ, Wong E, Davis JE, et al. Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2026. PMID: 42888040. doi:10.1111/bjh.70883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。